Myelodysplastic syndromes (MDS) and autoimmune conditions can overlap, and each may raise the risk of the other. Up to 30% of people with MDS also have an autoimmune disorder. Autoimmune conditions ...

Myelodysplastic syndromes (MDS) cause atypical bone marrow cells and low blood counts. This can lead to fatigue, shortness of breath, infections, bruising, and bleeding. Myelodysplastic syndromes (MDS ...

Myelodysplastic syndromes (MDS) are a group of blood cancers that affect the bone marrow and can result in a low levels of blood cells. When MDS affects red blood cells, it can lead to anemia in some ...

Successful Management of Neutropenic Sepsis Is Key to Better Survival of Patients With Blood Cancer in Sri Lanka: Real-World Data From the Resource-Limited Setting Myelodysplastic syndromes (MDS) ...

The European Medicines Agency (EMA) has given a positive recommendation for Rytelo (imetelstat) for the treatment of adult patients with transfusion-dependent anemia due to very low-, low-, or ...

Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes. Bruce Feinberg, DO: Amer, when we’re initiating, whether it’s ESAs [erythropoietin-stimulating ...

Robin Roberts appears on Good Morning America in New York, Wednesday, Nov. 23, 2011. (AP Photo/Charles Sykes) On Monday, Good Morning America anchor Robin Roberts announced to viewers that she has ...

Bexmarilimab and Vidaza achieved high response rates in higher-risk myelodysplastic syndrome, meeting the phase 2 BEXMAB trial's primary endpoint. The treatment demonstrated a 63% objective response ...

Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).

Rytelo (imetelstat) is a medicine used to treat myelodysplastic syndromes (MDS). MDS is a rare group of disorders that affect your blood cells. Most people who get MDS are 65 years of age or older, ...